Marion Bankstahl

Prof. Dr. Marion Bankstahl


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2013 in Neurobiology of Disease
Verified
Journal Article
Closed access
FNF.M. Noe
F.M. Noe
NPN. Polascheck
N. Polascheck
FFF. Frigerio
F. Frigerio
MBMarion Bankstahl
Marion Bankstahl
TRT. Ravizza
T. Ravizza
AVAnnamaria Vezzani
Annamaria Vezzani

1 September 2009 in Experimental Neurology
Verified
Journal Article
Closed access
CMChristine J. Müller
Christine J. Müller
IGIna Gröticke
Ina Gröticke
MBMarion Bankstahl
Marion Bankstahl
WLWolfgang Löscher
Wolfgang Löscher

1 July 2010 in Experimental Neurology
Verified
Journal Article
Closed access
NPNadine Polascheck
Nadine Polascheck
MBMarion Bankstahl
Marion Bankstahl
WLWolfgang Löscher
Wolfgang Löscher

17 December 2009 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
CKClaudia Kuntner
Claudia Kuntner
JBJens P. Bankstahl
Jens P. Bankstahl
MBMarion Bankstahl
Marion Bankstahl
JSJohann Stanek
Johann Stanek
TWThomas Wanek
Thomas Wanek
Oliver LangerOliver Langer
Oliver Langer

1 April 2013 in Drug Metabolism and Disposition
Verified
Journal Article
Closed access
PDF file
JBJens Bankstahl
Jens Bankstahl
MBMarion Bankstahl
Marion Bankstahl
KRKerstin Römermann
Kerstin Römermann
TWThomas Wanek
Thomas Wanek
JSJohann Stanek
Johann Stanek
CKClaudia Kuntner
Claudia Kuntner
Elacridar (ELC) and tariquidar (TQD) are generally thought to be nontransported inhibitors of P-glycoprotein (Pgp) and breast cancer resistance protein (BCRP), but recent data indicate that they may also be substrates of these multidrug transporters (MDTs). The present study was designed to investigate potential transport of ELC and TQD by MDTs at the blood-brain barrier at tracer doses as used in positron emission tomography (PET) studies. We performed PET scans with carbon-11-labeled ELC and TQD before and after MDT inhibition in wild-type and transporter-knockout mice as well as in in vitro transport assays in MDT-overexpressing cells. Brain entrance of [11C]ELC and [11C]TQD administered in nanomolar tracer doses was found to be limited by Pgp- and Bcrp1-mediated efflux at the mouse blood-brain barrier. At higher, MDT-inhibitory doses, i.e., 15 mg/kg for TQD and 5 mg/kg for ELC, brain activity uptake of [11C]ELC at 25 minutes after tracer injection was 5.8 ± 0.3, 2.1 ± 0.2, and 7.5 ± 1.0-fold higher in wild-type, Mdr1a/b(−/−,) and Bcrp1(−/−) mice, respectively, but remained unchanged in Mdr1a/b(−/−)Bcrp1(−/−) mice. Activity uptake of [11C]TQD was 2.8 ± 0.2 and 6.8 ± 0.4-fold higher in wild-type and Bcrp1(−/−) mice, but remained unchanged in Mdr1a/b(−/−) and Mdr1a/b(−/−)Bcrp1(−/−) mice. Consistent with the in vivo findings, in vitro uptake assays in Pgp- and Bcrp1-overexpressing cell lines confirmed low intracellular accumulation of ELC and TQD at nanomolar concentrations and increased uptake at micromolar concentrations. As this study shows that microdoses can behave pharmacokinetically differently from MDT-inhibitory doses if a compound interacts with MDTs, conclusions from microdose studies should be drawn carefully.